Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Presbv (Presbyopia Vejarano) tears: non-invasive solution for presbyopia

Poster Details

First Author: L.Vejarano COLOMBIA

Co Author(s):                        

Abstract Details

Purpose:

To evaluate the predictability, reproducibility, efficacy and reliability of this innovative NON-invasive treatment for ameliorating Presbyopia.

Setting:

20 Presbyopic patients who received treatment with PresbV Tears, 9 Emetropes, 5 post Lasik in their youth and 6 post PresbV LASIK (Vejarano Method). Fundacion Oftalmologica Vejarano,Popayán, Colombia

Methods:

Prospective study of the results in Pseudoaccommodation and real Accommodation (subjective and objectively (with OQAS and iTracey)), refraction, visual acuity corrected and uncorrected for far and near distance, refractive change, pupil size, endothelial cell count, Schirmer test, IOP, Keratometry, Pachymetry and ACD using the PresbV Tears only one drop in each eye (not monovision).

Results:

The average age was 49-65 years old within a range of 41-57, the measurements were taken previously, half an hour, 1, 2, 3, 4 and 5 hours later and 1 week and 1 month after. Globally the results are: improving one line of vision for far and three for near, minimal changes in pupil size, ACD, mild myopic shift only in the first hour and no changes in endothelial cell count and Schirmer test, decrease IOP in 2 mm of Hg at 4 hours and the keratometry get steep in the first hour typically showing the accommodation stimulus.

Conclusions:

This is a promising, non-invasive and adjuvant solution for Presbyopia patients; generating enough independence of glasses for the most activities in the normal life of the patients with no risks neither secondary effects.

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented

Back to Poster listing